BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...

Scientists from UNIGE have developed synthetic molecules that mimic antibodies. They could revolutionize the treatment of ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Professor Janice Walshe, a medical oncologist, explains how the diagnosis process works when it comes to breast cancer, as ...

A Berkshire teacher is set to take on a Pink Ribbon Walk after her own battle against cancer. Katy Headland, 39, from Newbury, was diagnosed with stage two HER2 negative breast cancer in January 2024, ...

Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.

With the demonstration of the ability to measure HER2 circulating tumour cells status dynamically over time, Angle said it successfully completed its contract with Eisai. Separately, Angle said ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...